Status:
COMPLETED
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
Lead Sponsor:
GlaxoSmithKline
Conditions:
Neoplasms, Breast
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study will be a randomized 3-treatment, cross-over study to evaluate the bioavailability of lapatinib administered after a high or low-fat meal.
Eligibility Criteria
Inclusion
- Metastatic, histologically confirmed breast cancer that over-expresses ErbB2 (3+ by IHC; FISH or CISH positive).
- Is at least 18 years of age and not greater than 65 years of age.
- Is male or female. A female is eligible to enter and participate in the study if she is of:
- Non-childbearing potential (i.e. physiologically incapable of becoming pregnant), including any female who: has had a hysterectomy; has had a bilateral oophorectomy (ovariectomy); has had a bilateral tubal ligation, or is post-menopausal (a demonstration of total cessation of menses for ≥ 1 year) or in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \> 40 MlU/ml and estradiol \< 40 pg/ml (\<140 pmol/L) is confirmatory.
- Childbearing potential, has a negative serum pregnancy test at Screening and agrees to one of the following: double-barrier contraception (condom with spermicidal jelly, foam, suppository, or film; diaphragm with spermicide; or male condom and diaphragm); complete abstinence from sexual intercourse from two weeks prior to administration of the study drug, throughout the active study treatment period; vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.
- Is able to swallow and retain oral medication.
- ECOG performance status 0 to 2.
- Adequate bone marrow function.
- Hemoglobin ≥ 9 gm/dL.
- Absolute granulocyte count ≥1,500/mm3 (1.5 x 109/L).
- Platelets ≥ 75,000/mm3 (75 x 109/L).
- Calculated creatinine clearance (CrCl) ≥ 50 ml/min based on Cockcroft and Gault
- Total bilirubin ≤ 1.5 X upper limit of normal of institutional values and INR ≤ 1.5.
- Alanine transaminase (ALT) ≤ three times the upper limit of the institutional values or ≤ five times ULN with documented liver metastases.
- Has a left ventricular ejection fraction (LVEF) within the normal institutional range based on ECHO or MUGA.
- Life expectancy of ≥12 weeks
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Exclusion
- Is pregnant or lactating.
- Has malabsorption syndrome, a disease affecting gastrointestinal function, or resection of the stomach or small bowel.
- Has current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment).
- Has evidence of symptomatic or uncontrolled brain metastases or leptomeningeal disease. Subjects with brain metastases treated by surgery and/or radiotherapy are eligible if neurologically stable and do not require steroids or anticonvulsants.
- Is considered medically unfit for the study by the investigator as a result of the medical interview, physical exam, or screening investigations.
- Has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the investigational product such as gefitinib \[Iressa\] and erlotinib \[Tarceva\].
- Has received treatment with any investigational drug in the previous four weeks.
- Has received chemotherapy, immunotherapy, biologic therapy or hormonal therapy for the treatment of cancer within the past 14 days, with the exception of mitomycin C which is restricted for the past six weeks.
- Is receiving any prohibited medication within the timeframe indicated on the prohibited medication list for this study.
- Has physiological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
- Has inadequate venous access for protocol-related blood draws.
- Clinically significant electrocardiogram (ECG) abnormality.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
- Has consumed red wine, seville oranges, grapefruit or grapefruit juice and/or kumquats, pummelos, exotic citrus fruit (i.e. star fruit, bitter melon), grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
Key Trial Info
Start Date :
March 6 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 22 2011
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00821054
Start Date
March 6 2009
End Date
March 22 2011
Last Update
November 13 2017
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Buffalo, New York, United States, 14263
2
GSK Investigational Site
Greenville, South Carolina, United States, 29605
3
GSK Investigational Site
Edmonton, Alberta, Canada, T6G 1Z2
4
GSK Investigational Site
Montreal, Quebec, Canada, H2W 1T8